Result of AGM

RNS Number : 8473U
Entelos Inc.
20 May 2008

For immediate release
20 May 2008
ENTELOS, Inc.

("Entelos" or "the Company")

Result of AGM
Entelos, Inc. announces that at its Annual General Meeting held earlier today all resolutions put to the meeting were duly passed.

Enquiries:

Entelos, Inc.
Jill Fujisaki, VP Investor Relations Tel: +1 650 572 5400
KBC Peel Hunt, Ltd (Nominated Advisor and Broker)
Capel Irwin/David Anderson Tel +44 (0) 20 4718 8900
Buchanan Communications
Lisa Baderoon/ Mary-Jane Johnson Tel +44 (0) 20 7466 5000

Notes for Editors
About Entelos
Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize
the way medicines and health-care related consumer products are discovered, developed, and utilized. The Company leverages its proprietary
in silico disease models, "virtual populations", and toxicology reference systems to develop safer and more effective drugs for
pharmaceutical R&D and to help improve the quality of health-care related consumer products. Entelos provides customized technology and
research services to global pharmaceutical, health-care, and consumer products companies in arthritis, cardiovascular diseases, asthma,
obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products. The Company is also
developing a model in oncology and is collaborating with the FDA to build a model of drug-induced liver injury. Entelos also offers
cost-effective drug development capabilities through its strategic alliance with India-based Jubilant Biosys Ltd.

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCDBLBLVEBEBBQ

Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024